Oxidative alterations in Alzheimer's disease

Brain Pathology

Volumn 9, Issue 1, 1999, Pages 133-146

  Markesbery, William R ^a   Carney, John M ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b EVOTEC AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; ACUTE PHASE PROTEIN; CARBOHYDRATE; CYTOKINE; DNA; LIPID; POLYUNSATURATED FATTY ACID; PROTEIN;

ALZHEIMER DISEASE; BRAIN INJURY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; FATTY ACID OXIDATION; HUMAN; HUMAN TISSUE; INFLAMMATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; OXIDATIVE STRESS; SENILE PLAQUE;

EID: 0032902974     PISSN: 10156305     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1750-3639.1999.tb00215.x     Document Type: Conference Paper

References (136)

1. Aksenov MY, Aksenov MV, Payne RM, Smith CD, Markesbery WR, Carnay JM (1997) The expression of creatine kinase isoenzymes in neocortex of patients with neurodegenerative disorders: Alzheimer's and Pick's disease. Exp Neurol 146: 458-465
2. Aksenov MY, Tucker HM, Nair P, Aksenova MV, Butterfield DA, Estus S, Markesbery WR (1998) The expression of key oxidative stress handling genes in different brain regions in Alzheimer's disease. Accepted J Mol Neurosci
3. Ames BN, Shigenaga MK, Hagen TM (1995) Mitochondrial decay in aging. Biochem Biophys Acta 1271: 165-170
4. Balazs L, Leon M (1994) Evidence of an oxidative challenge in the Alzheimer's brain. Neurochem Res 19: 1131-1137
5. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW (1993) Cytotoxicity of microglia. Glia 7: 111-118
6. Bauer MKA, Lieb K, Schulze-Osthoff K, Berger, M, Gebicke-Haerter PJ, Bauer J, Fiebich BL (1997) Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem 243: 726-731
7. Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38: 357-366
8. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson BJ, Bassett SS, Mclnnis MG, Albert MS, Hyman BT, Tanzi RE (1998) Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 19: 357-360
9. Blanc EM, Kelly JF, Mark RJ, Waeg G, Mattson MP (1997) 4-Hydroxynonenal, an aldehydic product of lipid peroxidation, impairs signal transduction associated with muscarinic acetylcholine and metabotropic glutamate receptors: possible action on G alpha (q/11). J Neurochem 69: 570-580
10. Braughler JM, Hall ED (1989) Central nervous system trauma and stroke. I. Biochemical considerations for oxygen radical formation and lipid peroxidation. Free Radic Biol Med 6: 289-301
11. Bredt DS, Snyder SH (1994) Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem 63: 175-195
12. Brett J, Schmidt A, M., Van SD, Zou Y-S, Weidman E, Pinsky D, Nowgrod R, Neeper M, Przysiecki C, Shaw AEA (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143: 1699-1712
13. Bruce-Keller AJ, Li YJ, Lovell MA, Kraemer PJ, Gary DS, Brown RR, Markesbery WR, Mattson MP (1998) 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats. J Neuropathoi Exp Neurol 57: 257-267
14. Burbaeva GS, Aksenova MV, Makarenko IG (1992) Decreased level of creatine kinases BB in the frontal cortex of Alzheimer patients. Dementia 3: 91-94
15. Carpenter AF, Carpenter PW, Markesbery WR (1993) Morphometric analysis of microglia in Alzheimer's disease. J Neuropathoi Exp Neurol 52: 601-608
16. Castellani, Smith MA (1998) Iron regulatory proteins in Alzheimer's disease. J Neuropathol Exp Neurol 57: 511
17. Chagnon P, Betard C, Robitaille Y, Cholette A, Gauvreau D (1995) Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. NeuroReport 6: 711-715
18. Chang JW, Coleman PD, O'Banion MK (1996) Prostaglandin G/H synthase-2 (cyclooxygenase-2) mRNA expression is decreased in Alzheimer's disease. Neurobiol Aging 17: 801-808
19. Cohen G, Werner P (1994) Free radicals, oxidative stress and neurodegeneration, In: Neurodegenerative Diseases, Calne DB (ed.), Chapter 10, pp 139-161, W. B. Saunders Co., Philadelphia,PA, USA
20. Colton CA, Gilbert DL (1987) Production of Superoxide anions by a CNS macrophage, the microglia. FEBS Lett 223: 284-288
21. Colton CA, Snell J, Chernyshev O, Gilbert DL (1994) Induction of Superoxide anion and nitric oxide production in cultured microglia. Ann. NY Acad. Sci. 738: 54-63
22. Connor JR, Menzies SL, St. Martin SM, Mufson EJ (1992 a) A histochemical study of iron, transferrin and ferritin in Alzheimer's diseased brains. J Neurosci Res 31: 75-83
23. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ (1992 b) Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 31: 327-335
24. Connor JR, Menzies SL (1995) Cellular management of iron in the brain. J Neurol Sci 134: 33-44
25. Cornett CR, Markesbery WR, W.D. (1998) Imbalances of trace elements related to oxidative damage in Alzheimer's disease brain. Neurotoxicology 19: 339-346
26. Coyle JT, Puttfarcken P (1993) Oxidative stress, glutamate and neurodegenerative disorders. Science 262: 689-695
27. Danielson UH, Esterbauer H, Mannervik B (1987) Structure-activity relationships of 4-hydroxyalkenals in the conjugation catalysed by mammalian glutathione transferases. Biochem J 247: 707-713
28. Davies KJ (1995) Oxidative stress: the paradox of aerobic life. Biochem Soc Symp 61: 1-31
29. Deibel MA, Ehmann WD, Markesbery WR (1996) Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress. J. Neurol Sci 143: 137-142
30. Ehmann WD, Markesbery WR, Alauddin M, Hossain TIM, Brubaker EH (1986) Brain trace elements in Alzheimer's disease. Neurotoxicology 7: 197-206,
31. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4- hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128
32. Evans PH (1993) Free radicals in brain metabolism and pathology. Br Med Bull 49: 577-587
33. Fleming J, Joshi JG: Ferritin (1987) Isolation of aluminumferritin complex from brain. Proc Natl Acad Sci USA 84: 7866-7870
34. Gabbita SP, Lovell MA, Markesbery WR (1998) Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 71: 2034-2040
35. Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, Viteck MP, Gajdusek DC (1989) lnterleukin1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 86: 7606-7610
36. Good PF, Perl DP, Bierer LM, Schmeidler J (1992) Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann. Neurol. 31: 286-292
37. Good PF, Werner P, Hsu A, Olanow CW, Perl DP (1996) Evidence of neuronal oxidative damage in Alzheimer's disease. Am J Pathol 149: 21-28
38. Grundke-Iqbal I, Fleming J, Tung Y-C, Lassmann H, Iqbal K, Joshi JG (1990) Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol 81: 105-110
39. Gsell W, Conrad R, Hickethier M, Sofic E, Frolich L, Wichart I, Jellinger K, Moll G, Ransmayr G, Beckmann H, Riederer P (1995) Decreased catalase activity but unchanged Superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 64(3): 1216-1223
40. Hajimohammadreza I, Brammer M (1990) Brain membrane fluidity and lipid peroxidation in Alzheimer's disease. Neurosci Lett 112: 333-337
41. Hall ED, Braughler JM (1989) Central nervous system trauma and stroke. II. Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic Biol Med 6: 303-313
42. Halliwell B, Gutteridge JMC (1989) Free Radicals in Biology and Medicine, 2nd Edition, Clarendon Press: Oxford University Press, New York, NY, USA
43. Harris ME, Hensley K, Butterfield DA, Leedle RA, Carney JM (1995) Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons. Exp Neurol 131: 193-202
44. Hensley K, Carney JM, Hall N, Shaus W, Butterfield DA (1994 a) Electron paramagnetic resonance investigations of free radical induced alterations in neocortical synaptosomal membrane protein infrastructure. Free Radic. Biol. Med. 17: 321-331
45. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, Lovell M, Markesbery WR, Butterfield DA (1994 a) Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J Neurochem 65: 2146-2156 1995
46. Hermon M, Cairns N, Egly JM, Fery A, Labudova O, Lubec G (1998) Expression of DNA excision-repair-crosscomplementing proteins p80 and p89 in brain of patients with Down syndrome and Alzheimer's disease. Neurosci Lett 251: 45-48
47. Hirai K, Smith MA, Wade R, Perry G (1998) Vulnerable neurons in Alzheimer disease accumulate mitochondrial DNA with the common 5KB deletion. J Neuropathol Exp Neurol 57: 511
48. Hunt JV, Smith CC, Wolff SP (1990) Autooxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 39: 1420-1424
49. Hunt JV, Wolff SP (1991) Oxidative glycation and free radical production: a causal mechanism of diabetic complications. Free Radic Res Commun 12-13: 115-123
50. Hunt JV, Bottoms MA, Mitchinson MJ (1993) Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental differences in proposed mechanisms of glucose oxidation and oxtdant production. Biochem J 291: 529-535
51. Jagust WJ (1998) Neuroimaging of dementing disorders. In: Neuropathology of Dementing Disorders, Markesbery WR (ed). Chapter 2, pp. 25-55, Arnold: London, UK
52. Jefferies WA, Food MR, Gabathuler R, Rothenberger S, Yamada T, Yasuhara O, McGeer PL (1996) Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin. Brain Res 712: 122-126
53. Kato K, Kurobe N, Suzuki R, Morishita R, Asano T, Sato T, lnagaki T (1991) Concentrations of several proteins characteristic of nervous tissue in cerebral cortex of patients with Alzheimer's disease. J Mol Neurosci 3: 95-99
54. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, Mattson MP (1997) Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid ß- peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 69: 273-284
55. Kennard ML, Feldman H, Yamada T, Jefferies WA (1996) Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease. Nat Med 2: 1230-1235
56. Kish SJ, Morito CL, Hornykiewicz O (1986) Brain glutathione peroxidase in neurodegenerative disorders. Neurochem Pathol 4: 23-28
57. Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ, Wilson JM, Distefano LM, Nobrega JN (1992) Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 59: 776-779
58. Klegeris A, Walker DG, McGeer PL (1994) Activation of macrophages by Alzheimer -amyloid peptide. Biochem Biophys Res Commun 199: 984-991
59. Kruman I, Bruce-Keller AJ, Bredesen D, Waeg G, Mattson MP (1997) Evidence that 4-hydroxynonenal mediates oxidative stress- induced neuronal apoptosis. J Neurosci 17:5089-5100
60. Lovell MA, Ehmann WD, Butler SM, Markesbery WR (1995) Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45:1594-1601
61. Lovell MA, Ehmann WD, Mattson MP, Markesbery WR (1997) Elevated 4- hydroxynonenal in ventricular fluid in Alzheimer's disease. Neurobiol Aging 18: 457-461
62. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR (1998 a) Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52
63. Lovell MA, Markesbery WR (1998 b) Decreased glutathione transferase in brain and ventricular fluid in Alzheimer's disease. Neurology, in press
64. Lovell MA, Gabbita SP, Markesbery WR (1998 c) Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem, in press
65. Lyras L, Cairns NJ, Jenner A, Jenner P, Halliwell B (1997) An assessment of oxidative damage to proteins, lipids, and DNA in brains from patients with Alzheimer's disease. J Neurochem 68: 2061-2069
66. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML (1998) Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp Neurol 150: 40-44
67. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP (1997 a) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid ß-peptide. J Neurochem 68: 255-264
68. Mark RJ, Pang Z, Geddes JW, Uchida K, Mattson MP (1997 b) Amyloid ß- peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci 17: 1046-1054
69. Markesbery WR, Lovell MA (1998) Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 19: 33-36
70. Marklund SL, Adolfsson R, Gottfries CG, Winblad B (1985) Superoxide dismutase isoenzymes in normal brains and in brains from patients with dementia of Alzheimer type. J Neurol Sci 67: 319-325
71. Marietta MA (1993) Nitric oxide synthase structure and mechanism. J Biol Chem 268: 12231-12234
72. 2+ concentration, and neurotoxicity and increase antioxidant enzyme activities in hippocampal neurons. J Neurochem 65: 1740-1751
73. McGeer PL, McGeer EG (1995) The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev 21(2): 195-218
74. McGeer PL, Schulzer M, McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47: 425-432
75. Mclntosh LJ, Trush MA, Troncoso JC (1997) Increased susceptibility of Alzheimer's disease temporal cortex to oxygen free radical-mediated processes. Free Radic Biol Med 23: 183-190
76. McMillian M, Kong LY, Sawin SM, Wilson B, Das K, Hudson P, Hong JS, Bing G (1995) Selective killing of cholinergic neurons by microglial activation in basal forebrain mixed neuronal/glial cultures. Biochem Biophys Res Commun 215: 572-577
77. Mecocci P, MacGarvey U, Kaufman AE, Koontz D, Shoffner JM, Wallace DC, Beal MF (1993) Oxidative damage to mitochondrial DNA shows marked age- dependent increases in human brain. Ann Neurol 34: 609-616
78. Mecocci P, MacGarvey U, Beal MF (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36: 747-751
79. Miatto O, Gonzalez RG, Buonanno F, Growdon JH (1986) In vitro 31p NMR spectroscopy detects altered phospholipid metabolism in Alzheimer's disease. Can J Neurol sci. 13: 535-539
80. Montine TJ, Amarnath V, Martin ME, Strittmatter WJ, Graham DG (1996 a) E-4- hydroxy-2-nonenal is cytotoxic and cross-links cytoskeletal proteins in P19 neuroglial cultures. Am J Pathol 148: 89-93
81. Montine KS, Kim PJ, Olson SJ, Markesbery WR, Montine TJ (1997) 4-hydroxy- 2-nonenal pyrrole adducts in human neurodegenerative disease. J Neuropathol Exp Neurol 56(8): 866-871
82. Montine TJ, Markesbery WR, Morrow JD, Roberts LJ (1998 a) Cerebrospinal fluid F2 isoprostane levels are increased in Alzheimer's disease. Ann Neurol 44: 410-413
83. Montine KS, Recch E, Neely MD, Sidell KR, Olson SJ, Markesbery WR, Montine TJ (1998 b) Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype. J Neuropathol Exp Neurol 57: 415-425
84. Morrow JD, Roberts LJ (1997) The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 36: 1-21
85. Mullaart E, Boerrigter ME, Swabb RR, Vijg J (1990) Increased levels of DNA breaks in cerebral cortex of Alzheimer's disease patients. Neurobiol Aging 11: 169-173
86. Mutisya EM, Bowling AC, Beal MF (1994) Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 63: 2179-2184
87. Münch G, Thome J, Foley P, Schinzel R, Riederer P (1997) Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Rev 23: 134-143
88. Namekata K, Imagawa M, Terashi A, Ohta S, Oyama F, Ihara Y (1997) Association of transferrin C2 allele with late-onset Alzheimer's disease. Hum Genet 101: 126-129
89. Neeper M, Schmidt AM, Brett J, Van SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:(21)14998-15004.
90. Nitsch RM, Blusztajn JK, Pittas AG, Slack BE, Growdon JH, Wurtman RJ (1992) Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci USA 89: 1671-1675
91. O'Banion MK, Miller JC, Chang JW, Kaplan MD, Coleman PD (1996) Interleukin 1-B induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J Neurochem 66: 2532-2546
92. Pappolla MA, Omar RA, Kim KS, Robakis NK (1992) Immunohistochemical evidence of oxidative stress in Alzheimer's disease. Am J Pathol 140: 621-628
93. Parker WD, Parks JK, Filley CM, Kleinschmidt-DeMasters BK (1994) Electron transport chain defects in Alzheimer's disease brain. Neurology 44: 1090-1096
94. Parker WD, Parks JK (1995) Cytochrome c oxidase in Alzheimer's disease brain: purification and characterization. Neurology 45: 482-486
95. Partridge RS, Monroe SM, Parks JK, Johnson K, Parker WD, Eaton GR, Eaton SS (1994) Spin trapping of azidyl and hydroxyl radicals in azide-inhibited rat brain submitochondrial particles. Arch Biochem Biophys 310: 210-217
96. Pettigrew JW, Moossy J, Withers G, McKeag D, Panchalingam K (1988) 31P nuclear magnetic resonance study of the brain in Alzheimer's disease. J. Neuropathol Exp Neurol 47: 235-248
97. Prasad MR, Lovell MA, Yatkin M, Dhillon H, Markesbery WR (1998) Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 23: 81-88
98. Premkumar DRD, Smith MA, Richey PL, Petersen RB, Castellani R, Kutty RK, Wiggert B, Perry G, Kalaria RN (1995) Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer's disease. J Neurochem 65: 1399-1402
99. Reiman EM, Caselli RJ, Yun LS, Chen K, Bandy D, Minoshima S, Thibodeau SN, Osborne D (1996) Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 334: 752-758
100. Richardson JS (1993) Free radicals in the genesis of Alzheimer's disease. Ann NY Acad Sci 695: 73-76
101. Roberts LJ, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, Dettbarn WD, Morrow JD (1998) Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 22: 13605-13612
102. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Wilson P (1993) Clinical trial of indomethacin in Alzheimer's disease. Neurology 43: 1609-1611
103. Roses AD (1996) Apolipoprotein E alleles as risk factors in Alzheimer's disease. Ann Rev Med 47: 387-400
104. Samudralwar DL, DiPrete CC, Ni BF, Ehmann WD, Markesbery WR (1995) Elemental imbalances in the olfactory pathway in Alzheimer's disease. J Neurol Sci 130:139-145
105. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336: 1216-1222
106. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA (1997) 4- Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 68: 2092-2097
107. Schipper HM, Cisse S, Stopa EG (1995) Expression of heme oxygenase-1 in he senescent and Alzheimer-diseased brain. Ann Neurol 37: 758-768
108. Schmidt A, M., Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M (1992) Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial surface. J Biol Chem 267(21): 14987-14997
109. Simonian NA, Hyman BT (1993) Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in the hippocampal formation. J Neuropathol Exp Neurol 52: 580-585
110. Simonian NA, Hyman BT (1994) Functional alterations in Alzheimer's disease: selective loss of mitochondrialencoded cytochrome oxidase mRNA in the hippocampal formation. J Neuropathol Exp Neurol 53:508-512
111. Smale G, Nichols NR, Brady DR, Finche CE, Horton WE (1995) Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 133: 225-230
112. Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA, Kaplan A, LaRue A, Adamson CF, Chang LEA (1995) Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273: 942-947
113. Smith CD, Carney JM, Starke-Reed PE, Oliver CN, Stadtman ER, Floyd RA, Markesbery WR (1991) Excess brain protein oxidation and enzyme dysfunction in normal aging and Alzheimer disease. Proc. Natl. Acad. Sci USA 88: 10540-10543
114. Smith MA, Taneda S, Richey PL, Miyata S, Van S-D, Stern D, Sayre LM, Monnier VM, Perry G (1994 a) Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 91: 5710-5714
115. Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, Wiggert B, Petersen RB, Perry G (1994 b) Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 145: 42-47
116. Smith MA, Sayre LM, Monnier VM, Perry G (1995) Radical AGEing in Alzheimer's disease. Trends Neurosci 18: 172-176
117. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N (1996) Oxidative damage in Alzheimer's. Nature 382: 120-121
118. Smith MA, Harris PLR, Sayre LM, Perry G (1997 a) Iron accumulation in Alzheimer disease is a source of redoxgenerated free radicals. Proc Natl Acad Sci USA 94: 9866-9868
119. Smith MA, Richey-Harris P, Sayre LM, Beckman JS, Perry G (1997 b) Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci 17: 2653-2657
120. Sohal RS (1997) Role of mitochondria and oxidative stress in the aging process. In: Mitochondria and Free Radicals in Neurodegeneration Diseases, Beal MF, Howell N, Bodis-Wollner I (eds.), Chapter 5, pp 91-107, Wiley-Liss, Inc: New York, NY, USA
121. Stadelmann C, Bruck W, Bancher C, Jellinger K, Lassman H (1998) Alzheimer disease: DNA fragmentation indicates increased neuronal vulnerability, but not apoptosis. J Neuropathoi Exp Neurol 57:456-464.
122. Stadtman ER (1992) Protein oxidation and aging. Science 257: 1220-1224
123. Su JH, Anderson AJ, Cummings BJ, Cotman CW (1994) Immunohistochemical evidence for apoptosis in Alzheimer's disease. NeuroReport 5: 2529-2533
124. Su JH, Deng G, Cotman CW (1997) Neuronal DNA damage precedes tangle formation and is associated with upregulation of nitrotyrosine in Alzheimer's disease brain. Brain Res 774: 193-197
125. Subbarao KV, Richardson JS, Ang LC (1990) Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 55: 342-345
126. Svennerholm L, Gottfries CG (1994) Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset (type I) and demyelination in late-onset form (type II). J. Neurochem. 62: 1039-1047
127. Uchida H, Stadtman ER (1992) Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci USA 89: 4544-4589
128. Vane JR, Bakhle YS, Botting RM (1998) Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol Toxicol 38: 97-120
129. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, Manogue K, Cerami A (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Natl. Acad. Sci. USA 91: 4766-4770
130. Wade R, Hirai K, Perry G, Smith MA (1998) Accumulation of 8-hydroxyguanosine in neuronal cytoplasm indicates mitochondrial damage and radical production are early features of Alzheimer disease. J Neuropathol Exp Neurol 57:511
131. Walker DG, Kim SU, McGeer PL (1995) Complement and cytokine gene expression in cultured microglia derived from postmortem human brains. J Neurosci Res 40: 478-493
132. Yamabe T, Dhir G, Cowan EP, Wolf AL, Bergey GK, Krumholz A, Barry E, Huffman PM, Dhib-Jalbut S (1994) Cytokine-gene expression in measles- infected adult human glial cells. J Neuroimmunol 49: 171-179
133. Van SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott CW, Caputo C, Frappier T, Smith MA, Perry G, Yen SH, Stern D (1994) Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 91: 7787-7791
134. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691
135. Yan SD, Zhu H, Fu J, Yan SF, Roher A, Tourtellotte WW, Rajavashisth T, Chen X, Godman GC, Stern D, Schmidt AM (1997) Amyloid-B peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci, USA 94: 5296-5301
136. Yatin SM, Aksenova M, Aksenova M, Markesbery WR, Aulick T, Butterfield DA (1998) Temporal relations between amyloid B-peptide-induced free radical oxidative stress and neuronal toxicity and neuronal defense responses. Submitted